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license (http://creativecommons.org/Summary Magnesium (Mg)-based biodegradable materials are promising candidates for the
new generation of implantable medical devices, particularly cardiovascular stents and ortho-
paedic implants. Mg-based cardiovascular stents represent the most innovative stent technol-
ogy to date. However, these products still do not fully meet clinical requirements with regards
to fast degradation rates, late restenosis, and thrombosis. Thus various surface coatings have
been introduced to protect Mg-based stents from rapid corrosion and to improve biocompati-
bility. Similarly, different coatings have been used for orthopaedic implants, e.g., plates and
pins for bone fracture fixation or as an interference screw for tendon-bone or ligament-bone
insertion, to improve biocompatibility and corrosion resistance. Metal coatings, nanoporous
inorganic coatings and permanent polymers have been proved to enhance corrosion resistance;
however, inflammation and foreign body reactions have also been reported. By contrast,
biodegradable polymers are more biocompatible in general and are favoured over permanent
materials. Drugs are also loaded with biodegradable polymers to improve their performance.
The key similarities and differences in coatings for Mg-based stents and orthopaedic implants
are summarized.
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Magnesium (Mg) is one of the lightest metals, exhibiting
good mechanical properties, biodegradability, and
biocompatibility [1,2], and has thus received great atten-
tion in the field of percutaneous coronary intervention (PCI)
[3] and orthopaedic applications [4,5]. The main applica-
tions of Mg-based implantable medical devices currently
include cardiovascular stents, bone fixation plates and pins,
and screws for tendon-bone or ligament-bone insertions.
The nature of their biodegradability makes Mg alloys look
promising in implant applications because there is no need
for secondary surgery to remove the implants [6]. Unfor-
tunately, due to low corrosion resistance, many problems
including hydrogen elution and decreasing mechanical
strength prior to the healing of the surgical regions have
also arisen during in vivo studies [7,8].
To prevent rapid corrosion, various surface modification
techniques have been used [9,10]. Among them, the
application of coatings has been documented as one of the
most effective [11]. In addition to corrosion prevention,
coatings can also provide a drug reservoir for Mg-based
biomedical implants. Many coating technologies have
been developed for Mg alloys, including inorganic coatings,
metal coatings, metallic oxide coatings, metallic hydroxide
coatings, chemical conversion coatings, nanoporous inor-
ganic coatings, and polymer coatings [11e17]. This paper
reviews the various coating techniques applied to Mg alloy
device scaffolds and also determines the role that coatings
play in stent functionality and orthopaedic implants. The
differences and similarities of coatings used in stents and
orthopaedic implants are also addressed.
Metal, metallic oxide, and metallic hydroxide
coatings
Metal coatings
Titanium (Ti) implantation has been shown to improve the
corrosion resistance of AZ91 alloy [18]. The vapour depo-
sition of aluminium (Al) has been applied to Mg-based alloys
and has been shown to decrease the degradation rate [19].
The downside of this Al deposition, however, is its low
biocompatibility. Al has also shown signs of corroding in
sodium chloride (NaCl) solution, an outcome that does not
suggest efficiency for an implant coating material [13].
Therefore further analysis of other more effective mate-
rials is needed for a better understanding of deposited
metal coatings that produce low toxicity values when
implanted. Gold was also investigated as a coating for Mg
alloy in another patent [20]. However, others workers have
demonstrated that stents coated with gold increase the risk
of restenosis [21].
Metallic oxide and metallic hydroxide coatings
A thin film of metallic oxide can provide an interface with
vascular milieu for a stent as well as enhancing its
biocompatibility [22]. Therefore some metallic oxides, such
as titanium dioxide and zirconium oxide, were coated onstents to improve their performance. A titanium-nitride-
oxide coating was investigated to reduce neointimal hy-
perplasia. Compared with stainless steel, two stents coated
with different titanium-nitride-oxide coatings showed bet-
ter biocompatibility and reduced neointimal area [23].
Another study investigated converting metallic poly-
crystalline oxides into an amorphous oxide to increase the
corrosion resistance of stents. The results indicated that an
amorphous oxide-coated stent was safer and more
biocompatible [24]. Earlier research suggests that nickel
(Ni)eTi stents may have a native oxide layer. By an elec-
tropolishing, heat treatment and passivation process, the
deformed native oxide layer on a NieTi stent can be
removed and a new uniform oxide layer will form. These
processes improved the corrosion resistance of NieTi stents
due to the uniformity of the oxide layer grown on the stent
surface [25]. Zirconium oxide [26], iridium oxide [27], and
noble metal oxides [28] have also been reported in patents
as coatings for stents. Another patent reported a multilayer
metal and metallic oxide coating for a stent: the inner
metallic layer was a noble metal or alloy and the outer
layer was iridium oxide [29].
The simplest method of generating a coating on an Mg
sample is to simply expose it to the environment (air and
water). This process, called passivation, exposes the sam-
ple to atmospheric humidity at a level sufficient to create a
Mg hydroxide layer on the outer surface; continuing to store
the sample in air creates an additional, beneficial, car-
bonate layer. Oxide layers usually provide better corrosion
protection than hydroxide layers. The Mg(OH)2 layer actu-
ally increases in thickness on the implant surface over time,
whereas the MgO layer stays at a relatively constant
thickness, but can be increased through thermal treatment
[30]. Also, alkaline solution treatment was also believed to
create a layer of Mg(OH)2, MgCO3, and MgO on the surface
of Mg alloys [14].Chemical conversion coating
Chemical conversion coating involves taking the surface of
the metal implant material and converting it into the
desired coating via a chemical or electrochemical process.
In the past, the process was performed to create chromate
layers because of its ability to provide effective corrosion
resistance. However harmful environmental outcomes arise
from the use of chromium (Cr) in chemical conversion
baths, therefore a Cr substitute must be found [31].
Metal phosphate compounds as a possible replacement
were investigated. The results of Chen et al [12] suggested
that the performance of these metal phosphate layers were
significantly dependent on the pre-treatments used to
make the layers more or less functional. For biomedical
applications, research shows that two potential coating
materials, fluoride-based layers and calcium phosphates,
can be applied.
Zhang et al [169] explored the preparation of calcium
phosphate coatings on an Mge1.0Ca alloy using electro-
chemical deposition. Enhanced corrosion resistance was
observed in Hank’s solutions. The thickness and morphology
of the coating had a significant effect on the corrosion
behaviour of this Mg alloy. Another investigation showed
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by an anodization and autoclaving process [33].
A MgF2 suspension was also synthesized to prevent
corrosion of the Mg alloy by Waltz et al [34] via a plasma
suspension spraying process. Li et al [35] studied the
corrosion resistance and cytotoxicity of MgF2-coated
Mge1Ca alloy by a vacuum evaporation deposition method.
The results indicated that MgF2-coated samples had much
lower degradation rate than uncoated samples. Moreover,
the MgF2 coating induced calcium phosphate deposition on
Mge1Ca alloys, which may promote bone cell growth.
Pereda et al [36] attempted to inhibit the corrosion of pure
Mg by fluoride treatments and their results showed that
different conditions could form different films on Mg. At
0.1 M fluoride solution treatment, KMgF3 was present on the
surface, whereas an MgF2 film was observed at 1 M fluoride
solution treatment. Another study investigated the
biocompatibility of fluoride-coated MgeCa alloys in a sub-
cutaneous mouse model. No visible inflammation reaction
or broad proliferative effect was observed, indicating suf-
ficient biocompatibility of fluoride-coated Mg alloys [37].
Studies from our group also showed that fluoride-coated
Mgerare earth element alloys had much better corrosion
resistance, endothelial attachment, growth, and prolifer-
ation (Fig. 1).
Nanoporous inorganic coatings
Nanoporous materials have a large surface area and
surface modifications at the nanoscale level can in-
crease biocompatibility [38]. Similarly, properties of
nanoporous coatings can be easily adjusted by the
manipulation of surface properties based on the specific
application [39].
Hydroxyapatite
Hydroxyapatite (HA) is one of the main inorganic compo-
nents of bone and teeth [40,41]. HA and some calcium
phosphate compounds are used as coatings because of their
biocompatibility and bioactivity [42]. Various HA andFigure 1 (A) Scanning electron microscopy image of fluoride coa
(B) Endothelialization on the same magnesium alloy surface coatecalcium phosphate coatings are summarized in Table 1
[41,44,48,55,108,150e161]. Calcium phosphate combined
with zoledronate was used as a bone substitute. In vitro
experiments on an unfractured rabbit bone indicated that
calcium phosphate loaded with zoledronate decreased the
area resorbed compared with calcium phosphate without
zoledronate [43]. Fluorine-doped hydroxyapatite (FHA)
coating is porous and loose and can ensure the long stability
of an Mg alloy implant. However, different electrodeposi-
tion coating processes can have an effect on the corrosion
resistance of FHA. For example, FHA coatings processed by
a pulse reverse current had better microstructure and
corrosion resistance than coatings processed by traditional
cathodic processes [44].
Micro-arc oxidation (MAO) technology is widely used in
surface modification. It has also been well investigated as a
coating on Mg alloys. Tang et al [45] compared the electro-
phoresis deposition (EPD) techniquewithMAO onMg alloys to
develop surface coatings for orthopaedic applications. Both
in vitro and in vivo tests indicated that the EPD technique
produced better corrosion resistance than MAO. Another
study explored the effect of MAO coatings on MgeCa alloys.
MAO treatment enhanced the corrosion resistance and
biocompatibility of the MgeCa alloy and the corrosion
resistance increasedwith voltage [46]. Some researchers are
trying to apply MAO technology to HA coatings. The role that
the MAO usually plays is to create a porous coating and then
HA or another calciumphosphate based coating is adhered to
the MAO coating. A three-layer coating was used to delay the
corrosion behaviour of Mg alloy AZ91. The inner layer was an
MgF2 conversion coating and the intermediate layer was
produced by MAOwith nanostructured hydroxyapatite as the
outer layer. Such coated alloys had enhanced corrosion
resistance as well as good cell adhesion in vitro [47]. Gao
et al [48] developed a two-layer HA coating to enhance Mg
alloy corrosion resistance and biocompatibility. The inner
layer of coating was produced by MAO technology with the
HA coating adhered to it as an outer layer. Electrochemical
tests showed that the corrosion potential of coated Mg alloys
increased by 161 mV. Only one layer of MAO coating was
necessary to protect pure Mg and the coated Mg had superior
corrosion resistance to pure Mg [49].ting morphologies on a magnesium alloy; scale bar Z 10.0 mm.
d with fluoride; scale bar Z 10.0 mm.
Table 1 Hydroxyapatite and calcium phosphate coated magnesium and magnesium alloys.
Reference Mg/Mg alloy HA/calcium
phosphate-related
compounds
In vitro/in vivo
tests
Results
Chen et al. [150] Mg HAeMg(OH)2 Electrochemical
and immersion
tests
Corrosion not
completely
stopped, but
moderated rapid
corrosion
Bornapour et al.
[151]
Mge0.5Sr HA and Mg(OH)2
(formed by
degradation in
SBF)
Immersion tests,
cytotoxicity
evaluation, in vivo
test in dog
Formation of an
Sr-substituted HA
layer in SBF; no
thrombosis during
3-week
implantation
Wen et al. [152] AZ31 HA Electrochemical
test, immersion
test
Alkaline-treated
HA more stable;
CaePeMg
deposition
inhibited further
corrosion
Zhang et al. [153] MgeAl, MgeCa Calcium
phosphate
Electrochemical
test, immersion
test
Coated samples
had a higher free
corrosion
potential, lower
corrosion current
densities, and
lower hydrogen
elution rate
Jamesh et al.
[154]
CP-Mg HA Potentiodynamic
polarization tests,
EIS studies
Three-fold charge
transfer resistance
increase in coated
CP-Mg; improved
corrosion-
protective ability
Wu et al. [155] AZ91D Calcium
phosphate/
chitosan
Immersion test in
PBS
Percentage of
Ca(OH)2 in
deposited layers
influenced
conversion rate
and composition
Hiromoto and
Tomozawa
[156]
AZ31 HA Immersion test,
polarization test
Reduced Mg2þ ion
release and
corrosion current
density
Abdal-hay [108] AZ31 HAePLLA In vitro
degradation test,
electrochemical
corrosion test,
mechanical
properties test,
cell viability assay
Improved
performance for
high corrosion rate
Feng and Han
[157]
ZK60A Calcium
polyphosphate
Immersion test,
electrochemical
test
Enhanced
corrosion
resistance
Xu et al. [55] MgeMneZn Calcium
phosphate
In vitro cell test,
in vivo study
Enhanced
cytocompatibility
Gao et al. [48] MgeZneCa Nano HA Bonding strength
test,
electrochemical
test, immersion
test
Corrosion current
density of coated
alloys decreased;
good corrosion
resistance
(continued on next page)
Table 1 (continued )
Reference Mg/Mg alloy HA/calcium
phosphate-related
compounds
In vitro/in vivo
tests
Results
Bakhsheshi-Rad
et al. [158]
MgeCaeZn Nano-HA/MgF2;
DCPD/MgF2
Electrochemical
test, immersion
test
Enhanced
polarization
resistance and
corrosion
potential of
coated alloys
Meng et al. [44]
Wang et al.
[159]
MgeZneCa
MgeZneCa
Fluorine-doped HA
Ca-deficient HA
Electrochemical
test, immersion
test
Coating adhesion
test,
electrochemical
test, SSRT test
PRC coating higher
corrosion
resistance, lower
corrosion rate,
compared with
TED coating.
Increased Ecorr
value of coated
alloys; delayed
corrosion of
coated alloys
Rojaee et al. [47] AZ91 Nano HA In vitro bioactivity
evaluation,
electrochemical
test
Higher corrosion
resistance of
coated alloys
Jo et al. [160] Mg HA, MgF2 Immersion test,
in vitro cell test,
in vivo test
Improved
corrosion
resistance and
bioactivity of
coated Mg
Zhang et al. [41] AZ91D Calcium
phosphate/
chitosan
Scratch test,
immersion test
Optimized
fabrication
parameters;
enhanced
corrosion
protection
Niu et al. [161] MgeNdeZneZr Brushite Immersion test,
electrochemical
test, cytotoxicity
evaluation,
in vitro cell
adhesion test,
haemolysis test,
in vivo test
Enhanced
corrosion test;
reduced
haemolysis;
produced less gas;
good surface
bioactivity
DCPD Z dicalcium phosphate dehydrate; EIS Z electrochemical impedance spectroscopy; HA Z hydroxyapatite; PBS Z phosphate-
buffered solution; PLLAZ poly-l-lactic acid; PRC = pulse reverse current; SBFZ simulated body fluid; SSRTZ slow strain rate tensile;
TED Z traditional cathodic process.
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HA and calcium phosphate compound coatings have been
applied in orthopaedics. Mg has been associated with the
mineralization of calcified bones and teeth [50]. Moreover,
research has shown that Mg ions can improve bone cell
adhesion on the surface of implants [51] and HA can pro-
mote bone cell adhesion and proliferation [52,53]. Also, the
mechanical properties of Mg alloys are more similar to
those of bone than other alloys, thus decreasing stress-
shielding effects [7]. Therefore, HA-coated Mg alloys are
ideal biomaterials for orthopaedic applications and havebeen widely investigated to prove this idea [8,51,54,55]. HA
coatings applied to cardiovascular stents have also been
reported. Costa et al [56] studied HA coatings on stainless-
steel stents loaded with low-dose sirolimus. Clinical trials
demonstrated the antiproliferative effect and biocompati-
bility of HA. No patient had obvious neointimal hyperplasia
during the trial. Another study of drug-eluting stents with
HA coatings was conducted to evaluate platelet activation
and deposition. The results showed that in an ex vivo
model, a cobalteCr alloy coated with HA did not increase
platelet reactivity and adhesion in human blood compared
Table 2 Synthesized polymer coatings for magnesium and
magnesium alloys.
Reference Mg/Mg alloys Polymers
Xu and
Yamamoto [104]
Mg PLLA, PCL
Chen et al. [9] Mg PLLA, PCL
Li et al. [113] Mge6Zn PLGA
Lu et al. [162] AZ81 PLLA, PLGA
Zomorodian
et al. [163]
AZ31 PEI, diethylene
triamine, HA
Scharnagl
et al. [121]
AZ31 PEI
Truong et al. [164] MgeMn alloy Polypyrrole
Yfantis et al. [165] AZ31 Polyacrylicepolypyrrole
Wang et al. [166] MgeZneMn PTMC
Liu et al. [167] WE43 Chitosan, PSS,
polyelectrolyte
Adden [168] Mg þ rare
earth
elements
Polyphosphazene
PLLA Z poly-l-lactic acid; PCL Z poly(ε-caprolactone);
PLGA Z poly(lactide-co-glycolide); PEI Z poly(ether imide);
PTMC Z poly(1,3-trimethylene carbonate); PSS Z poly(styrene
sulfonate).
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bility of HA [57]. However, some work has indicated that
calcium phosphate might cause vascular calcification and
cell mineralization [58e61].Solegel processed coatings
Solegel application is a process in which inorganic pre-
cursors undergo various reactions to form a three-
dimensional molecular network [62]. Solegel coatings can
form a dense barrier to protect corrosive metal substrates
and can be used to synthesize coatings with controlled
properties [63]. Several attempts to produce inorganic
coatings by the solegel method have been reported.
Different solegel films were coated on Mg alloys, including
titanium dioxide [64] and a methyltriethox-
ysilaneetetraethoxysilane mixture [65]; both showed good
corrosion resistance.Figure 2 Polymer properties affecting drug-eluting stent
(DES) performance [112].Polymer coatings
Polymer coatings can be used to enhance corrosion resis-
tance and the abrasion and wear properties of Mg alloys
[66]. Polymer coatings can also provide mechanical support
or serve as a drug vehicle for controlled release [67].
Natural polymers
Comparedwith synthesized polymers, natural polymers have
much higher biocompatibility [68]. Some natural polymers,
such as collagen [69e71] and chitosan [72e76] have been
used as coatings for stents and demonstrated to have good
biocompatibility. Collagen coatings have also been used in
orthopaedic implants for bone regeneration [77]. A novel
tripolymer composed of collagen, RGD (Arg-Gly-Asp) pep-
tide, and chondroitin sulfate was produced to coat Ti im-
plants to enhance bone healing [78]. Chitosan is also awidely
used coating for orthopaedic tissue-engineering materials
[79,80]. Some peptides, such as GFOGER (glycine-phenylal-
anine-hydroxyproline-glycine-glutamate-arginine), have
also been investigated in orthopaedic tissue healing or bone
repair [81,82]. However, both collagen and chitosan may
cause an immunological response [83] and activate com-
plement and blood coagulation [84]. Another natural poly-
mer, bacterial cellulose (BC), because of its high mechanical
strength, high water content, and good biocompatibility
[85], has been widely used in vascular grafts or as a vascular
replacement [86e89], in wound healing [90] and in tissue-
engineering scaffolds [91,92]. Composites formed by BC
mixed with other substances, e.g., poly(vinyl alcohol), as a
coating for stents was reported in a patent [93]. BC was also
used as a tablet coating for a drug-release system [94].
Moreover, as a biodegradable coating, the end degradable
product of BC is glucose, which is non-toxic to the body.
These studies suggest that BC has a great potential as a
biodegradable coating for drug-eluting stents (DES) and or-
thopaedic implant applications; more work is needed to
explore such possibilities.
Synthesized polymers
Most polymer coatings in cardiovascular and orthopaedic
applications are synthesized polymers. This is a result of the
easily altered properties of synthesized polymers through
the manipulation of the synthesis condition or other modi-
fications. For polymers to be used as coatings in these ap-
plications, the prevention of rapid corrosion with good
biocompatibility and controlled drug release are of great
interest. Table 2 [9,104,113,121,163e168] summarizes the
synthesized polymers used for Mg and Mg alloy coatings.
Synthesized polymers used in DES and orthopaedic im-
plants can be permanent or biodegradable. Permanent
polymers can allow controlled drug release and remain
after the drug is completely released [95,96]. Polymer
properties affecting DES performance are summarized in
Fig. 2[112]. The polymers used in the first and second
generations of DES are permanent. They can reduce
angiographic restenosis and demonstrate effectiveness in
PCI. However, tests show that they will cause late stent
thrombosis [97]. Moreover, long-stay polymers can cause
124 J. Ma et al.inflammatory reactions [98]. To solve the problems that
permanent polymers introduce, various kinds of biode-
gradable polymers, such as poly-l-lactic acid (PLLA) [99]
and poly(lactide-co-glycolide) (PLGA) [100,101], were syn-
thesized and tested; both had good chemical properties,
low immunogenicity and toxicity, and predictable biodeg-
radation kinetics [102].
PLLA is a common biodegradable polymer with good
mechanical properties and biocompatibility. Moreover, the
end biodegradable product can be removed by body fluids
and then metabolized by the liver and kidneys [103]. Xu and
Yamamoto [104] compared PLLA with another biodegrad-
able polymer, poly(ε-caprolactone) (PCL) as a coating to
protect Mg. The results showed that PLLA had a better
adhesion strength with Mg substrates than PCL and that
more cells were more proliferative on PLLA. Interestingly,
the early performance of PLLA-coated DES was similar to a
bare metal stent, though the long-term performance was
not studied [105]. In vitro dynamic degradation of pure Mg
with PLLA and PCL coatings showed that PCL had better
corrosion resistance in modified simulated body fluid solu-
tion than PLLA [9]. Wong et al [106] reported a polymer
fabricated by PCL and dichloromethane to enhance the
performance of AZ91 alloy in orthopaedic applications. The
results demonstrated improved corrosion resistance and
good cell biocompatibility. Gollwitzer et al [107] showed
that a PLLA coating for orthopaedic implants based on
three different alloys had good stability. Abdal-hay et al
[108] studied an HA-doped PLLA coating with respect to the
bioactivity and corrosion behaviour of AZ 31 alloy as an
orthopaedic implant; the coated samples showed a better
biocompatibility and bending strength.
PLGA has been used in drug-delivery systems [109,110]
and in tissue engineering for decades [102,111]. It can be
hydrolysed in vivo by breaking ester linkages into lactic and
glycolic acids, which are non-toxic [112]. In vitro degrada-
tion tests on PLGA as a coating for Mge6Zn alloy indicated
that it corroded slower and was more suitable for cell
attachment than bare Mge6Zn alloy [113]. Another study
compared in vitrodegradationwith in vivo changes for PLGA-
coated DES. The coating degradation rate was similar in both
in vitro and in vivo tests. However, polymer degradation in a
real vascular bed may give different results [114]. Ostrowski
et al [115] used various concentrations of PLGA to control the
thickness of coatings in orthopaedic applications. Although
PLLA and PLGA were well investigated and demonstrated
acceptable biocompatibility, some tests reported foreign
body reactions with PLLA [116,117] and PLGA [118].
Poly(ether imide) (PEI) has good mechanical properties
and is stable at high temperatures and has therefore been
explored as a coating for Mg alloys. da Conceicao and co-
workers [119,120] and Scharnagl et al [121] studied PEI as a
coating for the Mg alloy AZ31. Thin layers of PEI showed high
resistance to corrosionwhen exposed to a 3.5%NaCl solution.
This could be due to the formation of Mg polyamate, which
increased the corrosion impedance of the PEI coating.Coatings and biocompatibility
Although coatings can usually enhance the corrosion resis-
tance of Mg-based implants, sometimes the coatingmaterial itself may cause a chronic inflammatory response,
especially for permanent polymer coatings [122]. A coating
with good biocompatibility should not produce obvious
foreign body reactions, blood coagulation, nor inflamma-
tion [123]. The physical and chemical properties of coat-
ings determine their biocompatibility. Surface properties
such as surface ligands [32], molecular chirality [124],
surface patterns [125], surface roughness [126], and
chemical coatings [127,128] can regulate cell behaviour
significantly, thus having an effect on biocompatibility.
Moreover, composites formed by combining coatings and
other chemicals could enhance biocompatibility. For
example, BC combined with gelatin has a better bioactivity
and biocompatibility than BC alone [129]. Composite
coatings produced by the solegel process showed a higher
compatibility than coatings produced by MAO [130]. In DES,
drugs of the “limus” family [57,95,99,131] and paclitaxel
[95,132,133] can help inhibit smooth muscle cell prolifer-
ation. Another approach to improve the in vivo perfor-
mance of stents is to promote endothelialization. Vascular
endothelial growth factor can be loaded on to coatings to
simulate endothelialization [98,123]. In orthopaedic im-
plants, antibiotics are loaded on to coatings to reduce
inflammation and infection [134,135].Coatings for controlled drug release
In addition to enhanced biocompatibility and corrosion
resistance, coatings can also be used to control the release
rate of drugs. Some inorganic coatings, such as aluminium
oxide, have been applied in drug-delivery systems.
Aluminium oxide mixed with PLLA and PMMA (polymethyl
methacrylate) has been investigated as a coating for drug
release [112,136]. Nanoporous aluminium oxide, as a drug
carrier, has also been reported [137,138]. A chitosan- and
PLGA-coated titanium oxide nanotube to control drug
release and enhance osteoblast adhesion was explored.
Depending on the thickness of the polymers, reduced burst
release (from 77% to >20%) and extended overall release
(from 4 days to 30 days) were observed [139]. Kikuchi and
Okano [140] reviewed pulsatile control of drug release using
hydrogels. Coatings can provide a reservoir for drugs and
controlled drug release. Sustained drug release is essential in
preventing an inflammation response and reducing late
restenosis. The drug release kinetics of various DES samples
was similar. Many DES samples had a burst release at an early
stage (24e36 hours) and then a sustained release for at least
30 days, followed by reduced neointimal hyperplasia and
restenosis [112,141]. It was found that themorphology of the
coating surface had no effect on the amount of drug released
[142]. PLLA, a widely used biodegradable polymer coating in
DES, is also a good candidate for controlled drug release.
Some factors, such as the solvent removal rate [143], the
matrix coated on PLLA [144], and microsphere processing
parameters [145], were explored for a PLLA microsphere.
Copolymers of PLGA and mPEG [monomethoxy poly(-
ethyleneglycol)] nanoparticles was also investigated for
polymer degradation and drug release [146].
The most common mechanisms of drug release are
diffusion and degradation [147,148]. For diffusion, the
coating acts as a rate control membrane. Degradation-
Figure 3 Differences and similarities: coating purposes and functions for stents and orthopaedic implants.
Magnesium stents and orthopaedic implant coatings 125controlled drug release is based on the degradation of the
polymer that covered the drug reservoir. It has been shown
that porosity and size had effects on the drug release
mechanisms of PLGA [149].
Similarities and differences in the coatings
used in stents and orthopaedic implants
The main purpose of the coatings used in Mg-based implants
is to prevent rapid corrosion and improve the biocompati-
bility of the implants. Most surface modification methods
can be used in both applications. However, the surface
modification methods may vary because of the different
cell types the coatings may interface with. For stents,
biodegradable polymers with good biocompatibility and
ideal controlled drug release profiles are of great interest.
Although some biodegradable polymers have been reported
in orthopaedic applications, the most commonly investi-
gated coatings are still HA and calcium phosphate com-
pounds because of their structural and constituted
similarities to bone. In fact, HA-coated Mg alloys have been
well studied and display good biocompatibility in ortho-
paedic applications. However, they may not be a good
choice for DES because of potential vascular calcification.
Drug-eluting orthopaedic implants based on Mg alloys have
not been well explored to date. The differences and simi-
larities in coatings for orthopaedic implants and stents are
summarized in Fig. 3.
Conclusion
Mg-based biomaterials have a great potential in cardiovas-
cular and orthopaedic applications due to their biode-
gradability, biocompatibility, and appropriate mechanical
properties. However, they also have the limitation of low
corrosion resistance and suboptimal biocompatibility.
Coating technology is one of the leading approaches used to
overcome these problems.
Surface coatings played an important role in the devel-
opment of stents. Stent technology emerged in the 1980s
and developed rapidly from bare metal stents to coated DES
stents. Mg-based stents represent the latest generation ofbiodegradable stents and offer appealing features in clin-
ical applications. There have been several clinical trials
with promising outcomes on such Mg-based stents. Coatings
on Mg-based stents can vary from metal and inorganic
coatings to biodegradable coatings. Among these, biode-
gradable polymer coatings with drug-eluting features might
be a better choice because of their advanced biocompati-
bility and capability to reduce late restenosis compared
with other coatings. In the future design of coatings for Mg-
based stents, novel biodegradable polymers or copolymers
should be explored to further enhance biocompatibility
with sustained control of drug release. Moreover, new drugs
that can inhibit smooth muscle cell proliferation and
reduce neointimal hyperplasia while promoting endotheli-
alization are preferred.
In orthopaedic applications, HA and calcium phosphate
compounds have many advantages over other coatings,
such as structural and constituted similarity, and promoting
bone cell adhesion and proliferation. There are fewer re-
ports on orthopaedic implants with drug-eluting features. It
would be interesting to use drug-eluting orthopaedic im-
plants with controlled release to achieve an even better
healing process.
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